Ralston S H, Cowan R A, Robertson A G, Gardner M D, Boyle I T
Acta Endocrinol (Copenh). 1984 Aug;106(4):556-63. doi: 10.1530/acta.0.1060556.
Plasma concentrations of 1.25 dihydroxycholecalciferol were measured in 44 patients with malignancy associated hypercalcaemia and related to other hormonal regulators of calcium metabolism. Immunoreactive PTH concentrations were suppressed in all but 2 patients and, as a group, patients with hypercalcaemia of malignancy had lower 1.25 dihydroxycholecalciferol concentrations than normocalcaemic cancer patients. 1.25 dihydroxycholecalciferol concentrations were clearly detectable in a significant proportion (43%) of hypercalcaemia cases however, suggesting that in these patients the active vitamin D metabolite may contribute to the pathogenesis and maintenance of the hypercalcaemia by stimulating bone resorption, and/or by increasing absorption of calcium from the intestine. Measurement of plasma 1.25 dihydroxycholecalciferol concentration does not provide a wholly reliable method for distinguishing the hypercalcaemia of malignancy from primary hyperparathyroidism.
对44例恶性肿瘤相关性高钙血症患者的血浆1,25 - 二羟胆钙化醇浓度进行了测定，并与钙代谢的其他激素调节因子进行了关联分析。除2例患者外，所有患者的免疫反应性甲状旁腺激素浓度均受到抑制，总体而言，恶性肿瘤性高钙血症患者的1,25 - 二羟胆钙化醇浓度低于血钙正常的癌症患者。然而，在相当比例（43%）的高钙血症病例中，1,25 - 二羟胆钙化醇浓度明显可测，这表明在这些患者中，活性维生素D代谢产物可能通过刺激骨吸收和/或增加肠道对钙的吸收，从而促进高钙血症的发病机制并维持高钙血症状态。测定血浆1,25 - 二羟胆钙化醇浓度并不能提供一种完全可靠的方法来区分恶性肿瘤性高钙血症和原发性甲状旁腺功能亢进症。
